Current Clinical Trials


    LIBERATE is a randomized controlled clinical trial comparing use of bupivacaine with the adjuncts dexamethasone and epinephrine to liposomal bupivacaine in interscalene nerve block for shoulder arthroplasty patients.

  • CANCER: Genomic Profiling IMPACT (MSK 12-245)

    The purpose of this genomic profiling study is to determine whether certain genes in cancer may be abnormal.

  • CANCER: Pancreatic Cancer MSK 16-1066

    The purpose of this study is to test any good and bad effects of the study drug called PEGPH20. PEGPH20 alone is considered investigational. The Food and Drug Administration (FDA) has not approved the marketing or sale of PEGPH20, but have authorized its use in research studies with humans. PEGPH20 could shrink the cancer but it also can cause side effects. PEGPH20 is an enzyme that breaks down a specific tissue component called hyaluronan produced by some tumors. Pancreatic tumors often have a large amount of hyaluronan. The removal of hyaluronan from tumors may decrease tumor growth.

  • CANCER: Renal Cancer EA8143 (PROSPER)

    This trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with or without nivolumab in treating patients with kidney cancer that is limited to a certain part of the body (localized).

  • CANCER: HEME MSK 16-024 Leukemia Registry

    Observational Study to Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia

  • CANCER: Colorectal Cancer NRG GI004

    Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy With or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

  • CANCER: Pancreatic Cancer Tyme-88-PANC

    A Phase II Multi-Center Study of SM-88 in Patients with Pancreatic Cancer Whose Disease Has Progressed or Recurred after/on First Line Chemotherapy.

  • CANCER: Hodgkin Lymphoma CA209-812

    Randomized, Open-label, Phase 3 Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Participants With Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 812).

  • CANCER: Non-Hodgkin Lymphoma MOR208C204

    A Phase 2/3, Randomised, Multicentre Study of MOR208 With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT).

  • CANCER: Non-Hodgkin Lymphoma INCB 50465-203

    A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor in Relapsed or Refractory Follicular Lymphoma (CITADEL-203).

  • CANCER: Bladder Cancer MSK 16-1428

    The purpose of this study is to test the safety of the study drug, atezolizumab, when combined with the standard chemotherapy drugs, gemcitabine and cisplatin (or GC). This study will help researchers begin to understand whether combining GC with atezolizumab is better, the same, or worse than the usual approach of using GC alone.

  • CANCER: Lung Cancer BPI 2358-103

    The primary purpose of this study is to compare the overall survival of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease.

  • CANCER: Lung Cancer CA209-816-00

    The purpose of this study is to determine the safety and effectiveness of nivolumab plus ipilimumab or nivolumab plus chemotherapy compared to chemotherapy alone in the treatment of Early Stage Non-Small Cell Lung.

  • CANCER: Melanoma S1512

    This pilot phase II trial studies how well pembrolizumab works in treating patients with desmoplastic melanoma (DM) that can or cannot be removed by surgery. Monoclonal antibodies, like pembrolizumab, may block specific proteins which may strengthen the immune system and control tumor growth.

  • PSYCH: Neural Architecture of Social Emotional Processing and Regulation in Autism Spectrum Disorder

    This study delineates the temporal dynamics of the neural networks underlying social behaviors and emotional processing in relation to the diagnosis of autism spectrum disorder (ASD) and its social traits.

  • CANCER: Advanced Solid Tumors - FIVE Prime

    This is a three-part, open-label, safety, tolerability, and PK study of FPA144. Patients will be enrolled in Part 1 (A or B, dose escalation) or Part 2 (dose expansion) of the study, but not both.

  • CANCER: Ovarian Cancer Tesaro (FIRST)

    This is a global, multicenter, randomized, double-blind, controlled Phase 3 study in patients with newly diagnosed, Stage III or IV non mucinous epithelial ovarian, fallopian tube, or peritoneal cancer (collectively referred to as "ovarian cancer").

  • CANCER: Ovarian Cancer NRG-GY005

    This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory).

  • CANCER: Brain Cancer BN003

    This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery.

  • CANCER: MSK 17-031 (AML, MDS)

    The purpose of this study is to determine the activity of SY-1425 in relapsed/refractory acute myeloid leukemia (AML) patients, relapsed/refractory higher-risk myelodysplastic syndrome (MDS) patients (SY-1425 administered as a monotherapy or in combination with daratumumab), newly diagnosed treatment naïve AML patients who are unlikely to tolerate standard intensive chemotherapy (SY-1425 administered as a monotherapy or in combination with azacitidine), or lower-risk myelodysplastic syndrome (MDS) patients (SY-1425 administered as a monotherapy) who are positive for a RARA biomarker.

  • CANCER: Lung Cancer EA5142

    This phase III ALCHEMIST trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer.

  • CANCER: Lung Cancer E4512

    This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK).

  • CANCER: Lung Cancer AO81105

    This phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery.

  • CANCER: Breast Cancer MSK 17-585

    The purpose of this study is to test the safety of the study drug neratinib in combination with a standard chemotherapy drug called capecitabine at different doses to find out what effects, if any, it has on people.

  • CANCER: Breast Cancer TRIO033

    A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer.

  • CANCER: Brain Tumors MSK 17-261

    The purpose of this study is to test any good and bad effects of a study drug called abemaciclib (LY2835219) in patients with recurrent brain tumors.

  • CANCER: Multiple Myeloma - Amgen

    A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2)

  • CANCER: Breast Cancer S1418

    This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

  • CANCER: Thoracic Cancer Helsinn ANAM-17-20

    A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

  • CANCER: Gynecologic Cancer GOG 3018/VBL-111-701

    The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.

  • CANCER: Gynecologic Cancer MSK 17-180

    The purpose of this study is to test the safety of nivolumab and find out what affects, if any, nivolumab has on people and their risk of gynecologic cancer. The investigators also want to find out what effects, good or bad, nivolumab has on the patient and their cancer.

  • CANCER: Pancreatic Cancer MSK 19-239

    A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

  • CARDIO: Research Volunteers Wanted to Examine Vascular Function in Testicular and Hodgkins Cancer Survivors

    Research volunteers are wanted for examination of vascular function in testicular and Hodgkins cancer survivors. Participants must be 20-55 year old men previously treated for testicular cancer to be eligible. Participants who finish the study will receive free health information and financial compensation for their time.

  • PSYCH: Children of Parents with Alzheimer's Needed for Research on Brain Structure/Function

    Children of parents with alzheimer's are needed for research on brain structure/function. To be eligible individuals must be between the ages of 40 and 60, have a mother or father diagnosed with dementia/Alzheimer's after age 60, not be currently exercising, be willing to exercise 3 times per week for 6 months at Hartford Hospital, and be willing to undergo an MRI scan.

  • PSYCH: Healthy Volunteers Needed for Neuroimaging (Brain Scan) Study

    Investigators at The Anxiety Disorders Center at the Institute of Living/Hartford Hospital are recruiting participants without psychiatric problems for a neuroimaging (brain scan) study. We are offering a study that involves undergoing a neuroimaging (brain) scan while also participating in tasks that will examine your brain functioning.

  • PSYCH: Participants Needed for Sickle Cell/Brain fMRI Research Study

    This research study intends to understand how pain affects the brains of people with sickle cell disease. Healthy volunteers who are African-American and between the ages of 15-30 years are eligible. One 3-hour visit will be required and you will be compensated for your time!

  • PSYCH: Ketamine for Treatment-Resistant Depression

    This clinical research study is being conducted to evaluate an investigational medication for treatment-resistant depression. We are currently enrolling patients for a clinical research study to look at the effectiveness and dosing requirements of an investigational medication that may help with the symptoms of depression.

  • PSYCH: Clinical Research Study on Pediatric and Adolescent Depression is Now Enrolling Participants

    Does your child have depression? If so, s/he may be eligible to participate in a new research study being conducted by Dr. Salma Malik testing the effects of Vilazodone for the treatment of Depression. Participants must be 7 to 17 years of age and generally healthy.

  • PSYCH: Researchers seeking adolescents with and without ADHD, ages 9-18

    The Olin Neuropsychiatry Research Center at The Institute of Living is conducting a study of adolescents with ADHD ages 9-18 and healthy adolescents ages 9-18 to look at how the brain functions during decision-making in cognitive tasks. The study will require at least 1 visit to complete interviews with clinical staff and MRI scans. Qualified volunteers will be compensated $20 per hour for participation.

  • PSYCH: Researchers Seeking Adults with Autism Spectrum Disorders, Ages 18-40

    The Olin Neuropsychiatry Research Center at The IOL is conducting a study of adults with autism spectrum disorders (ASD) ages 18-40 to look at how our brains process social interactions and how it is different in individuals with ASD. The study may require two or more visits to complete interviews with clinical staff, MRI scans and an EEG. Qualified volunteers are compensated $20/hour for their time.

  • PSYCH: Researchers Seeking Participants for an Adult Depression Observational Study

    The Burlingame Research Center at The Institute of Living is conducting a study on patients ages 18-64 that are currently taking an anti-depressant and responding to this therapy. This study will last up to 12 months and financial compensation for time and travel may be provided.

  • PSYCH: Healthy Adults Sought For Research Study

    The Olin Neuropsychiatry Research Center at The Institute of Living is looking for healthy adults 18-60 with no significant history of mental illness. Participation will include: interviews and questionnaires, pencil and computer games, and an MRI. Qualifying persons will be compensated $20 per hour for their time. Lunch provided.

  • PSYCH: Participants with a Family History of Alcoholism Needed for Research Study

    Are you a healthy, right-handed adult between the ages of 18 and 35? You may qualify to participate in a research study at The Olin Neuropsychiatry Research Center at the IOL. Individuals matching that description who have relatives with alcoholism or a history of alcoholism are eligible to participate in this research study.

  • PSYCH: Depression in Pediatric and Adolescents

    The Burlingame Center for Psychiatric Research and Education is currently recruiting patients 7-17 years of age for a double-blind, clinical trial using Vilazodone for the treatment of pediatric and adolescent major depressive disorder. After completion of the 8-week study, subjects are eligible for a 6-month open-label trial of Vilazodone.

  • PSYCH: Sertraline Pediatric Registry (SPRITES)

    This non-interventional study will examine the risks and benefits of up to 3 years of treatment with sertraline on cognition, emotional and physical development, and pubertal maturation in children ages 6 to 14 years. Recruitment Needs: Patients ages 6-14 diagnosed with an anxiety or depressive disorder that are starting sertraline or starting therapy but not taking sertraline, with an IOL psychiatrist or psychologist. This study will not alter treatment regimen.

  • PSYCH: Research Study for Adults Treated for Depression

    The purpose of this study is to compare the accuracy and reliability of self-administered memory and thinking skills tests taken on an iPad tablet against the same tests administered by a doctor. The method for administering these tests could be used in future clinical studies when a study medication is being researched.

  • PSYCH: Help for Hoarding at No Cost

    The Anxiety Disorders Center at the Institute of Living/Hartford Hospital is conducting a study for people with Hoarding Disorder.

  • PSYCH: Healthy Volunteers Needed for Research Study

    The Anxiety Disorders Center at the Institute of Living/Hartford Hospital is recruiting participants with no current or lifetime history of psychiatric problems for a research study.

  • CARDIO: PULSE Pilot Study

    The Department of Preventive Cardiology is seeking individuals with high blood pressure for an exercise training study. You may qualify if you have (or think you have) high blood pressure; 18 years or older; non-smoker; and currently exercise less than two days per week.

  • CANCER: Gynecologic Cancer 264

    This trial studies Paclitaxel and Carboplatin to see how well they work compared with Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in treating patients with sex cord-ovarian stromal tumors (gastrointestinal) that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has returned (recurrent).

  • CANCER: Lung Cancer Alchemist A151216

    This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been, or will be removed by surgery.

  • CARDIO: Media and Heart Health

    Dr. Taylor from Hartford Hospital, Dr. Pescatello from the UConn Department of Kinesiology and Dr. Puhl from the UConn Rudd Center are conducting a research study to compare the effects of a short-term encounter to media videos on measures of mental and physical heart health in women.

  • CANCER: Yoga 4 Cancer

    If you are a patient at the Hartford HealthCare Cancer Institute at Hartford Hospital, or a patient with a musculoskeletal condition and a cancer history being seen through the Hartford HealthCare Bone & Joint Institute, you may be eligible for a research study investigating the benefits of yoga on mobility and quality of life.